Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Follow us on Twitter




Probi and Perrigo sign extensive pan-European agreement for launch of probiotic concepts

15:00 / 17 February 2021 Probi Press release

The semi-exclusive agreement enables Probi[®] and Perrigo to expand with premium probiotic digestive and immune health concepts into 14 European countries.

Under the agreement, Perrigo will launch three probiotic products as dietary supplements within the digestive and immune areas based on Probi's scientifically validated probiotic strains. The strains have been described in more than 100 publications since their discovery in the 1980's. The products have clinically documented positive effects and will be introduced under a new premier brand to complement and expand Perrigo's strong self-care portfolio. Financial terms were not disclosed.

Perrigo Executive Vice President and President of Consumer Self-Care International, Svend Andersen, stated "It is very important for Perrigo to enter the probiotic space together with a renowned probiotic innovator with a strong emphasis on scientifically validated probiotic concepts. This partnership will strengthen our self-care portfolio and enable Perrigo to gain a solid foothold within probiotics in many European countries. We are delighted to take this step together with Probi."

Probiotics are a high-growth segment where innovation and scientific support are key differentiators. The products covered in the agreement contain patent-protected probiotic strains, supported by state-of-the-art clinical studies, showing the clinical benefits in digestive and immune health for the consumer. The go-to-market plan covers 14 European countries. First launch is planned to take place in 2021.

"We see the collaboration between Probi and Perrigo as an important step in our commercial efforts in offering clinically documented probiotic products to European consumers in partnership with successful consumer healthcare companies. We are excited to enter a partnership with Perrigo, where we feel full alignment and confidence on important parameters like research, quality and performance. I strongly believe that this will strengthen the Probi brand on a global scale.", says Tom Rönnlund, CEO at Probi.

For further information, please contact:

Tom Rönnlund, CEO, Probi[®],
Phone: +46 46 286 89 40, E-mail:

Shane Judge, Marketing and Sales, Probi[®],
Phone: +46 72 399 48 57, E-mail:

Charlotte Beyerholm, Director Marketing & Global Communication, Probi[®],
Phone: +46 76 870 94 65, E-mail:



Probi[®] is a global company focused exclusively on researching, manufacturing, and delivering probiotics for supplements and functional food. We are experts at managing stable, live bacteria from R&D through every stage of the manufacturing process and are dedicated to making the health-enhancing benefits of probiotics available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical documentation. Since our founding in 1991 at Sweden's Lund University, Probi has expanded its operations to more than 40 markets. We hold more than 400 patents globally. Read more at Probi[®] is a registered trademark of Probi AB.


Perrigo Company plc (NYSE; TASE: PRGO) is a leading provider of Quality, Affordable Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Led by its consumer self-care strategy, Perrigo is the largest store brand OTC player in the U.S. in the categories in which it competes through more than 9,000 SKUs under customer `own brand' labels. Additionally, Perrigo is a Top 5 OTC company by revenue in Europe, where it markets more than 200 branded OTC products throughout 28 countries. The Company also commercializes and manufactures generic prescription products in the U.S. Visit Perrigo online at   

Show as PDF

Show original from Cision


This information was distributed by Cision